IDEAYA Biosciences, Inc. (IDYA) Form 424B5 — Jun 8, 2026
IDEAYA Biosciences is offering $300 million of common stock and pre-funded warrants to fund the continued clinical development and potential commercialization of darovasertib for uveal melanoma, as well as its broader precision oncology pipeline. The offering follows the presentation of positive Phase 2/3 data for darovasertib in combination with crizotinib at ASCO 2026, which met its primary endpoint of progression-free survival in metastatic uveal melanoma, and a new clinical collaboration with Roche for pancreatic cancer.
Key figures
- Gross Proceeds
- 300000000
- Last Sale Price
- 28.29
- Shares Outstanding
- 87856154
- Net Tangible Book Value
- 937300000
- Net Tangible Book Value Per Share
- 10.67
- Greenshoe Option Value
- 45000000
- Pre Funded Warrant Exercise Price
- 0.0001
Price after filing
Close on the filing date to close N calendar days later (from $31.48). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.